Dayli Partners

Founded in 2018, Dayli Partners is a venture capital firm based in Seoul, South Korea. It focuses on investing in bio ventures across various healthcare areas such as therapeutics, life sciences, medical devices, diagnostics, and fintech.

Yong-Chul Kim Ph.D

Managing Director

In-Ho Kwon Ph.D

Executive Managing Director

Seungho Lee

CEO

Past deals in South Korea

Kanaph Therapeutics

Series C in 2023
Kanaph Therapeutics is a biotechnology company focused on developing next-generation therapeutics for oncology and autoimmune diseases. Founded in 2019 and headquartered in Seoul, South Korea, the company engages in drug development activities ranging from discovery to early-stage clinical trials. Its therapeutic platform includes bi-specific antibodies, Fc-fusions, and small molecules. In oncology, Kanaph Therapeutics develops drugs with enhanced immuno-stimulatory activity in the tumor microenvironment for efficient tumor eradication. For autoimmune diseases, the company's pipeline features bispecific Fc-fusions that inhibit the alternative complement pathway, angiogenesis, and downstream complement activation. The company serves both Korea and the United States.

Medipixel

Series B in 2023
Medipixel, Inc. is a South Korean MedTech startup founded in 2017, specializing in artificial intelligence-based diagnostic software and semi-autonomous robotic systems for lung cancer and cardiac interventions. The company is comprised of a team of AI experts in computer vision, deep learning, and reinforcement learning, collaborating with top healthcare professionals, including those at Seoul Asan Medical Center, to enhance disease diagnosis and surgical procedures. Medipixel offers three primary solutions for intervention surgeons: an AI-based diagnosis tool that assists in identifying lesions during coronary angiography, a guide and planning solution that visualizes coronary arteries to facilitate guidewire manipulation, and an automated navigation engine that directs robotic units through arteries with real-time commands. These innovations aim to improve surgical outcomes and patient safety by reducing reliance on contrast agents and enhancing the precision of interventions.

CURAUM

Series B in 2023
Founded in 2017, CURAUM specializes in developing and selling oral care and sleep-related healthcare products. Its key offerings include Clium Cleaner for dental device cleaning, Clium S-Guard for managing obstructive sleep apnea and snoring, and the Clium System for personalized chronic sleeping disorder management.

HMC Networks

Series B in 2022
HMC Networks Co., Ltd. is a South Korean company established in 2013, based in Seoul, that specializes in providing management, consulting, and investment services tailored for hospitals and clinics. The company operates CareNation, a caregiver matching platform designed to connect caregivers, guardians, and patients, leveraging extensive industry expertise. Additionally, HMC Networks has divisions focused on medical devices, food products, and personal and joint care services. By utilizing big data, HMC Networks aims to drive service innovation and address information imbalances within the medical sector.

Y-Biologics

Venture Round in 2022
Y-Biologics Inc. is a biotechnology company based in Daejeon, South Korea, specializing in the discovery and development of novel antibody therapeutics, particularly in the field of immuno-oncology. Established in 2007, the company has developed a bispecific antibody platform technology known as AliCE, which maintains the structural integrity of the parental antibody, ensuring high binding affinity to cancer antigens. Additionally, Y-Biologics has created the Y-max ABL, a unique library of human antibodies, which supports its research and development efforts. The company is recognized for its contributions to the global immuno-chemotherapeutic drug market and also offers contract research services, aiming to advance its position within the biotechnology sector.

Ubix Therapeutics

Series B in 2022
Ubix Therapeutics, Inc. is a research and development company based in Seoul, South Korea, focused on the development of anti-cancer drugs utilizing a proprietary proteolysis targeting chimera platform. The company employs advanced inhibitor technology that degrades specific target proteins within cells, aiming to enhance therapeutic efficacy for various cancers. By binding to proteins associated with disease, Ubix Therapeutics seeks to provide life-saving medications for patients, thereby supporting both patients and medical professionals in the fight against cancer.

GI Innovation

Series C in 2021
GI Innovation, based in South Korea, specializes in bio-ventures by integrating basic science with translational innovation to develop biologics for global patients. Its strategic focus lies in immuno-oncology and inflammation/immunology diseases, leveraging the GI-SMART platform technology to efficiently optimize multi-targeting fusion protein therapeutics.

Master Meditech

Series A in 2021
Master Meditech Inc. is a biotechnology company based in Seoul, South Korea, specializing in the development of new pharmaceuticals through protein structure identification and medicinal chemistry. Established in 2019, the company focuses on leveraging advanced scientific techniques to discover innovative drug candidates, aiming to address various medical needs. With a commitment to enhancing therapeutic options, Master Meditech is positioned at the intersection of technology and healthcare, striving to contribute to advancements in the pharmaceutical industry.

Novelty Nobility

Series B in 2021
Novelty Nobility is a biotechnology company specializing in the research and development of antibody-based therapeutics targeting novel angiogenesis factors. The company focuses on ophthalmology and oncology, aiming to address unmet medical needs through innovative treatments.

CURAUM

Series A in 2021
Founded in 2017, CURAUM specializes in developing and selling oral care and sleep-related healthcare products. Its key offerings include Clium Cleaner for dental device cleaning, Clium S-Guard for managing obstructive sleep apnea and snoring, and the Clium System for personalized chronic sleeping disorder management.

Sugentech

Post in 2020
Sugentech Incorporated is an in-vitro diagnostic company based in Daejeon, South Korea, specializing in personal point-of-care testing products and personalized diagnosis solutions. Founded in 2011, the company focuses on developing innovative healthcare technologies by integrating biotechnology, information technology, and nanotechnology. Sugentech's product offerings include laboratory tests such as immunoblot processors and molecular diagnostics systems, as well as self-diagnostic home testing kits. Their portfolio features tests for various analytes, including C-reactive protein, procalcitonin, and troponin I, along with personal care tests like digital ovulation and pregnancy tests. Formerly known as Accugen Healthcare, Sugentech changed its name in 2013 to reflect its commitment to pioneering advancements in health diagnostics.

Medipixel

Series A in 2019
Medipixel, Inc. is a South Korean MedTech startup founded in 2017, specializing in artificial intelligence-based diagnostic software and semi-autonomous robotic systems for lung cancer and cardiac interventions. The company is comprised of a team of AI experts in computer vision, deep learning, and reinforcement learning, collaborating with top healthcare professionals, including those at Seoul Asan Medical Center, to enhance disease diagnosis and surgical procedures. Medipixel offers three primary solutions for intervention surgeons: an AI-based diagnosis tool that assists in identifying lesions during coronary angiography, a guide and planning solution that visualizes coronary arteries to facilitate guidewire manipulation, and an automated navigation engine that directs robotic units through arteries with real-time commands. These innovations aim to improve surgical outcomes and patient safety by reducing reliance on contrast agents and enhancing the precision of interventions.

MDimune

Series B in 2019
MDimune Inc. is a South Korean therapeutics company focused on developing innovative drug delivery systems. Founded in 2015 and based in Seoul, the company specializes in the creation of cancer therapeutics using immune cell-derived and stem cell-derived vesicles. Its research and development efforts encompass a range of therapeutic areas, including personalized cancer treatments, osteoarthritis, chronic obstructive pulmonary disease, and neurodegenerative disorders. MDimune's proprietary platform enables targeted delivery of drugs, allowing for the development of novel therapeutics that enhance treatment efficacy. The company provides its vesicle-based delivery solutions to biotech and pharmaceutical enterprises, thereby facilitating advanced therapeutic options for patients.

HUINNO

Series A in 2019
Founded in 2014, HUINNO is a digital health company headquartered in Boston with offices in New York and Seoul. It develops healthcare devices to monitor vital signs such as blood pressure, heart rate, ECG, and SpO2, offering real-time data analysis via its app and cloud-based ecosystem. The company focuses on improving chronic cardiac disease management through wearable technology and AI-driven analytics.

T&R Biofab

Post in 2019
T&R Biofab, established in 2013 and headquartered in Siheung, South Korea, is a biotechnology company specializing in the development of medical devices for transplantation and tissue regeneration. The company focuses on orthopedics, plastic surgery, and dentistry, offering products such as craniomaxillofacial meshes, dental meshes, and patient-specific implants. T&R Biofab utilizes innovative 3D printing technology to manufacture bioresorbable scaffolds that aid in the regeneration and reconstruction of tissues and organs.

Jeisys Medical

Post in 2019
Jeisys Medical, established in 2001 and headquartered in Seoul, South Korea, specializes in designing, developing, and manufacturing medical devices for various healthcare professionals, including plastic surgeons, dermatologists, and physicians. The company's portfolio spans across multiple treatment areas such as fat reduction, skin tightening, rejuvenation, and removal of unwanted pigments, tattoos, and acne. Notable products include LIPOcel, ULTRAcel Q+, and AcGen, marketed under brands like LIPOcel, ULTRAcel, and AcGen. Jeisys Medical distributes its products globally through a network of distributors.

SCM Lifescience

Series C in 2018
SCM Lifescience, founded in 2014, focuses on the research and development of innovative treatment options for challenging diseases. The company utilizes proprietary technologies for stem cell isolation and production, aiming to create new therapies that offer hope to patients and contribute to overall human welfare. Based in South Korea, SCM Lifescience is also involved in developing medicinal products and hair care solutions, leveraging its expertise in stem cell applications to address various health-related needs.

Y-Biologics

Series C in 2018
Y-Biologics Inc. is a biotechnology company based in Daejeon, South Korea, specializing in the discovery and development of novel antibody therapeutics, particularly in the field of immuno-oncology. Established in 2007, the company has developed a bispecific antibody platform technology known as AliCE, which maintains the structural integrity of the parental antibody, ensuring high binding affinity to cancer antigens. Additionally, Y-Biologics has created the Y-max ABL, a unique library of human antibodies, which supports its research and development efforts. The company is recognized for its contributions to the global immuno-chemotherapeutic drug market and also offers contract research services, aiming to advance its position within the biotechnology sector.

42Maru

Debt Financing in 2017
42Maru, Inc. is a South Korean technology company established in 2015, specializing in the development of advanced search engine technology designed for artificial intelligence applications. The firm focuses on creating a deep learning-based question-answering system that accurately interprets user intent and provides precise answers in real-time. Its technology encompasses various domains, including information retrieval, machine reading comprehension, and natural language processing, making it applicable across multiple sectors such as smart speakers, connected cars, chatbots, and home automation devices. 42Maru stands out in the market due to its high accuracy, efficient knowledge base expansion, and low operational costs. The company aims to penetrate the consumer market through strategic B2B2C alliances while supporting multiple languages for global expansion. With a team of experts led by a CEO with over 20 years of industry experience, 42Maru has formed partnerships with major telecommunications companies and financial institutions, positioning itself at the forefront of the emerging AI-driven search paradigm.

CURAUM

Founded in 2017, CURAUM specializes in developing and selling oral care and sleep-related healthcare products. Its key offerings include Clium Cleaner for dental device cleaning, Clium S-Guard for managing obstructive sleep apnea and snoring, and the Clium System for personalized chronic sleeping disorder management.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.